Literature DB >> 8883263

Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis.

D Mezzano1, R Tagle, O Panes, M Pérez, P Downey, B Muñoz, E Aranda, P Barja, S Thambo, F González, S Mezzano, J Pereira.   

Abstract

Several parameters of primary hemostasis and markers of activation of coagulation and fibrinolysis were measured in 48 patients with severe (creatinine clearance < 20 ml/min) chronic renal failure (CRF) without dialysis and disease or drugs affecting hemostasis. Bleeding time (BT) was prolonged in 25/48 patients, and was correlated with age of patients, severity of renal failure, hematocrit, impairment in platelet aggregation-secretion and decrease in platelet ATP content. Defects in von Willebrand factor played no role in the prolongation of the BT. Multivariate analysis showed that only platelet dysfunction and severity of renal disease were independent predictors of the BT in uremia. The platelet functional disorder was significantly correlated with a reduction in platelet ATP and ADP. High levels of plasma thrombin-antithrombin complexes (TAT), prothrombin fragment F1 + 2, fibrinogen and factor VIIc were observed in patients with CRF, as described in prethrombotic states. Plasmin-antiplasmin complexes (PAP), fibrinogen and fibrin degradation products (FgDP, FnDP) were significantly increased, and the activity of plasminogen activator inhibitor (PAI-1) was slightly reduced, denoting an activation of fibrinolysis. A negative correlation was found between platelet levels of ATP and ADP with plasma TAT, F1 + 2 and PAP. Furthermore, plasma PAI-1 activity was negatively correlated with the BT and was lower in patients with prolonged BT as compared with controls and patients with normal BT. These links between primary hemostasis and activation of coagulation and fibrinolysis suggest that increased intravascular generation of thrombin and/or plasmin is an important mediator of the defects in primary hemostasis, prolongation of the BT and, probably, bleeding in CRF.

Entities:  

Mesh:

Year:  1996        PMID: 8883263

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

Review 1.  Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.

Authors:  Nicola Ferri; Alberto Corsini; Stefano Bellosta
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

Review 2.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

3.  Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis.

Authors:  Thomas Pilgrim; Stefan Stortecky; Fabienne Luterbacher; Stephan Windecker; Peter Wenaweser
Journal:  J Thromb Thrombolysis       Date:  2013-05       Impact factor: 2.300

4.  Myocardial revascularization in patients with end-stage renal disease: comparison of percutaneous transluminal coronary angioplasty and coronary artery bypass grafting.

Authors:  K Ivens; F Gradaus; P Heering; F C Schoebel; M Klein; H D Schulte; B E Strauer; B Grabensee
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 5.  Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency.

Authors:  Ayman A El-Menyar; Jassim Al Suwaidi; David R Holmes
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

Review 6.  Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review.

Authors:  Homam Ibrahim; Sunil V Rao
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

7.  Mitigation of device-associated thrombosis and thromboembolism using combinations of heparin and tirofiban.

Authors:  Stacy Meola; Gregory Burns; Sivaprasad Sukavaneshvar; Kenneth Solen; Syed Mohammad
Journal:  J Extra Corpor Technol       Date:  2006-09

Review 8.  The emerging role of coagulation proteases in kidney disease.

Authors:  Thati Madhusudhan; Bryce A Kerlin; Berend Isermann
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

Review 9.  Anticoagulation in CKD and ESRD.

Authors:  Kelvin Cheuk-Wai Leung; Jennifer Marie MacRae
Journal:  J Nephrol       Date:  2019-01-28       Impact factor: 3.902

10.  Is there a cardiovascular protective effect of aspirin in chronic kidney disease patients? A systematic review and meta-analysis.

Authors:  Bo Qu; Yuhua He; Lihua Wu; Hongmei Lu; Haili Wu; Mingquan Li
Journal:  Int Urol Nephrol       Date:  2019-12-09       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.